Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Oncothyreon Inc. Stories

2012-02-28 07:05:00

SEATTLE, Feb. 28, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that it will conduct a conference call to discuss its full year and fourth quarter 2011 financial results and provide a review of its pipeline of products in development on Tuesday, March 6, 2012 at 4:30 p.m. Eastern Time. To participate in the call by telephone, please dial (877) 280-7291 (United States) or (707) 287-9361 (International). In addition, the call will be webcast live and can be...

2012-02-28 07:00:00

SEATTLE, Feb. 28, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will be presenting at the following upcoming investment conferences in March. Cowen and Company 32(nd) Annual Healthcare Conference Tuesday, March 6, 2012, 10:00 a.m. Eastern time in Boston, MA Barclays Capital Global Healthcare Conference Wednesday, March 14, 2012, 4:45 p.m. Eastern time in Miami, FL A live and archived webcast...

2012-02-07 07:00:00

SEATTLE, WA, Feb. 7, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will be presenting at the following upcoming investment conferences in February. 14thAnnual BIO CEO & Investor Conference Tuesday, February 14, 2012 at 2:30 p.m. Eastern time in New York, NY Citi 2012 Global Health Care Conference...

2012-01-05 15:15:00

SEATTLE, WA, Jan. 5, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced the promotion of Diana Hausman, M.D., to Chief Medical Officer.  Dr. Hausman joined Oncothyreon in August 2009 as Vice President, Clinical Development. "Diana has been instrumental in the advancement of our oncology pipeline, particularly our expansive clinical program for PX-866, a phosphatidylinositol-3-kinase (PI-3K) inhibitor currently in multiple Phase 2 clinical trials to evaluate the...

2011-12-20 07:00:00

SEATTLE, WA, Dec. 20, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for ONT-10, a therapeutic vaccine directed at cancers expressing MUC1. Upon completion of the FDA's review of the IND, Oncothyreon expects to initiate a Phase 1 trial of ONT-10. "We are pleased to announce the filing of this IND, which is a significant milestone for our therapeutic...

2011-12-07 07:00:00

SEATTLE, WA, Dec. 7, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will be presenting at the Oppenheimer 22(nd) Annual Healthcare Conference in New York on Wednesday, December 14, 2011 at 2:45 p.m. Eastern Standard Time. A live and archived webcast of the presentation will be accessible by visiting the Oncothyreon website www.oncothyreon.com under the "News & Events" section. About...

2011-11-13 14:35:00

SEATTLE, Nov. 13, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced the presentation of data from two Phase 1/2 trials of PX-866, an irreversible, pan-isoform phosphatidylinositol-3-kinase (PI-3K) inhibitor, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, California. Results presented highlighted findings from the Phase 1 dose-escalation portions of Phase 1/2 trials evaluating PX-866 in combination with...

2011-11-08 15:05:00

Company to Hold Conference Call at 4:30 p.m. EST Today SEATTLE, Nov. 8, 2011 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today reported financial results for the third quarter ending September 30, 2011. Net loss from operations increased to $6.4 million in the third quarter of 2011 from $4.3 million in the third quarter of 2010, and to $18.1 million for the nine months ended September 30, 2011 compared to $14.5 million for the comparable period in 2010. This increase in...

2011-11-08 07:00:00

SEATTLE, WA, Nov. 8, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that the company will be presenting at the Lazard Capital Markets 8(th) Annual Healthcare Conference in New York on Tuesday, November 15, 2011 at 9:30 a.m. Eastern Standard Time. A live and archived webcast of the presentation will be accessible by visiting the Oncothyreon website www.oncothyreon.com under the "News & Events" section. About Oncothyreon Oncothyreon is a biotechnology company...

2011-11-01 07:00:00

SEATTLE, WA, Nov. 1, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that it will conduct a conference call to discuss its third quarter 2011 financial results and provide a review of its pipeline of products in development on Tuesday, November 8, 2011 at 4:30 p.m. Eastern Standard Time. To participate in the call by telephone, please dial (877) 280-7291 (United States) or (707) 287-9361 (International). In addition, the call will be webcast live and can be...